PBU The Pension Fund of Early Childhood & Youth Educators Invests $4.80 Million in United Therapeutics Corporation $UTHR

PBU The Pension Fund of Early Childhood & Youth Educators acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 9,857 shares of the biotechnology company’s stock, valued at approximately $4,803,000.

Several other hedge funds have also modified their holdings of UTHR. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $317,617,000. Norges Bank purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $293,418,000. Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $157,390,000. Balyasny Asset Management L.P. raised its position in shares of United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after buying an additional 136,883 shares in the last quarter. Finally, Sofinnova Investments Inc. purchased a new position in United Therapeutics in the second quarter worth about $34,055,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on UTHR. Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Trading Up 0.4%

UTHR opened at $549.87 on Friday. The firm has a market cap of $23.34 billion, a P/E ratio of 20.30, a P/E/G ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a 50-day moving average of $568.23 and a 200 day moving average of $518.83.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $6.63 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,712,246.04. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This trade represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 624,043 shares of company stock valued at $351,649,680 over the last 90 days. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.